Trial Profile
A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 12 Feb 2021 Status changed from active, no longer recruiting to discontinued due to loss of funding.
- 23 Apr 2020 Status changed from suspended to active, no longer recruiting.
- 09 Apr 2020 Status changed from recruiting to suspended.